Pre-treatment predictors of response for assessing outcomes to standard treatment in infection with HCV genotype 3

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 2, 2011, Pages 64-68

  Qureshi, Saleem ^a   Batool, Uzma ^a   Iqbal, Mussarat ^a   Burki, Umar Farooq ^a   Khan, Naqeeb Ullah ^a  

^a Khan Research Labs General Hospital   (Pakistan)

Author keywords

Body weight; Chronic hepatitis C; Interferon; Predictors; Ribavirin; Steatosis; Sustained viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; RIBAVIRIN; RIBAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BODY WEIGHT; DEMOGRAPHY; FATTY LIVER; FEMALE; GENOTYPE; GROUPS BY AGE AND SEX; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RISK FACTOR; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79751485497     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Davis GL, Lau J Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26:122S-7S.
2. Mc Hutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon aifa-2b alone or in combination with Ribavirin as initial treatment of for chronic hepatitis C. N Engl J Med 1998; 339:1485-92. Comment in: p. 1549-50.
3. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600-09.
4. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998, 352:1426-32. Comment in: Lancet 1999; 353:499; author reply 500.
5. Mc Hutchison JG, Shad JA, Gordon SC, Morgan TR, Ling MH, Garaud JJ, et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using HCV RNA results during therapy. J Viral Hepat 2001; 8:414-20.
6. Fried MW. Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev Gastroentrol Disord 2004; 4:S8-13.
7. Frenci P. Predictors of responses to therapy for chronic hepatitis C. Semin Liver Dis 2004; 24:25-31.
8. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26:15S-20S.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
10. Manns M P, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65. Comment in: Lancet 2002; 359:263; author reply 264.
11. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002; 37:500-6.
12. Poynard T, Mc Hutchison J, Goodman Z. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-8. Comment in: p. 158.
13. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-9. Comment in: p. 1032-5.
14. Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha - interferon. J Hepatol 2001; 35:307.
15. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in genotype 2 or 3. N Engl J Med 2005; 352:2609 -17. Comment in: Acta Gastroenterol Latinoam 2007; 37:126-33.
16. Batool U, Qureshi S. Declining sustained virological response in hepatitis C. J Coll Physicians Surg Pak 2006; 16:187-91.
17. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47. Comment in: Hepatology 2008; 47:356; author reply 356-7.
18. Demiraran Y, Korkut E, Tamer A, Yorulmaz I, Kocaman B, Sezen G, et al. The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: a prospective, randomized study. Can J Gastroenterol 2007; 21:25-9.
19. Ghany M, Strader DB, Thomas D, Seeff L. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.